Skip links

Crysvita® (burosumab-twza)

Full Name Crysvita® (burosumab-twza)
Drug Crysvita
Manufacturer Kyowa Kirin North America
Route of Administration Subcutaneous
Site of Care Home or Healthcare Facility
Approved Indication The treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older and FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older
Disease Tumor-induced Osteomalacia (TIO); X-linked Hypophosphatemia (XLH)
Therapeutic Area Endocrinology & Bone Specialty
Enrollment Form Link Enrollment Form
Phone Number 800-240-7614
Fax Number 877-793-4897
Product Website